Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amneal Pharmaceuticals (AMRX)

Amneal Q4 2024 revenue rises 18% to $731 million; GAAP net loss $31 million

Mixed Impact 3 of 5 earnings Written later

Amneal reported fourth-quarter and full-year 2024 results on February 28, 2025. Net revenue rose 18% in the quarter and 17% for the year, while the GAAP net loss narrowed in the quarter but widened for the full year, and adjusted diluted EPS declined. The company also gave 2025 guidance for net revenue of $3.0 billion to $3.1 billion and adjusted EBITDA of $650 million to $675 million.

Key points

  • Q4 2024 net revenue was $731 million, up 18% from $617 million; GAAP net loss attributable to Amneal was $31 million, versus $99 million in Q4 2023.
  • Q4 2024 adjusted diluted EPS was $0.12, compared with $0.14 in Q4 2023.
  • Full-year 2024 net revenue was $2.79 billion, up 17%; GAAP net loss was $117 million, versus $84 million in 2023; adjusted diluted EPS was $0.58, down 9%.
  • 2025 guidance: net revenue of $3.0 billion to $3.1 billion, adjusted EBITDA of $650 million to $675 million, and adjusted diluted EPS of $0.65 to $0.70.

The filing

CompanyAmneal Pharmaceuticals (AMRX)
Form8-K, current report
Filed with the SECFeb 28, 2025, 6:13 AM ET
Accession number0001723128-25-000009

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 28, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.